139 related articles for article (PubMed ID: 2648838)
1. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer.
Rubin SC; Hoskins WJ; Hakes TB; Markman M; Reichman BS; Chapman D; Lewis JL
Am J Obstet Gynecol; 1989 Mar; 160(3):667-71. PubMed ID: 2648838
[TBL] [Abstract][Full Text] [Related]
2. Value of serum 125Ca levels: does the result preclude second look?
Potter ME; Moradi M; To AC; Hatch KD; Shingleton HM
Gynecol Oncol; 1989 May; 33(2):201-3. PubMed ID: 2703182
[TBL] [Abstract][Full Text] [Related]
3. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
4. Use of CA 125 to monitor patients with ovarian epithelial carcinomas.
Podczaski E; Whitney C; Manetta A; Larson JE; Kirk J; Stevens CW; Lyter J; Mortel R
Gynecol Oncol; 1989 May; 33(2):193-7. PubMed ID: 2703180
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinoma.
Meier W; Stieber P; Eiermann W; Schneider A; Fateh-Moghadam A; Hepp H
Gynecol Oncol; 1989 Oct; 35(1):44-6. PubMed ID: 2792900
[TBL] [Abstract][Full Text] [Related]
6. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Jun; 37(3):319-22. PubMed ID: 2190870
[TBL] [Abstract][Full Text] [Related]
7. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1992 Jun; 45(3):323-8. PubMed ID: 1612511
[TBL] [Abstract][Full Text] [Related]
8. Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation.
Mogensen O; Mogensen B; Jakobsen A; Sell A
Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1835-7. PubMed ID: 3220081
[TBL] [Abstract][Full Text] [Related]
9. Is CA-125 monitoring useful in patients with epithelial ovarian carcinoma and preoperative negative CA-125 serum levels?
Sevelda P; Rosen A; Denison U; Barrada M; Spona J; Salzer H
Gynecol Oncol; 1991 Nov; 43(2):154-8. PubMed ID: 1743558
[TBL] [Abstract][Full Text] [Related]
10. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
Meden H; Rath W; Teichmann A; Kuhn W
Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687
[TBL] [Abstract][Full Text] [Related]
11. CA 125 serum levels correlated with second-look operations among ovarian cancer patients.
Berek JS; Knapp RC; Malkasian GD; Lavin PT; Whitney C; Niloff JM; Bast RC
Obstet Gynecol; 1986 May; 67(5):685-9. PubMed ID: 3457330
[TBL] [Abstract][Full Text] [Related]
12. Plasma D-dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma.
Rose PG; Terrien JM; Baker S
J Surg Oncol; 1994 Jul; 56(3):168-71. PubMed ID: 8028348
[TBL] [Abstract][Full Text] [Related]
13. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
Göcze P; Vahrson H
Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
[TBL] [Abstract][Full Text] [Related]
14. Tumor markers of epithelial and stromal cell origin at second-look laparotomy in ovarian carcinoma.
Tomás C; Kauppila A
Gynecol Oncol; 1992 Jun; 45(3):279-83. PubMed ID: 1612504
[TBL] [Abstract][Full Text] [Related]
15. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
[TBL] [Abstract][Full Text] [Related]
16. The role of the CA 125 assay in the management of ovarian cancer.
Niloff JM
Oncology (Williston Park); 1988 Aug; 2(8):67-76. PubMed ID: 3275060
[TBL] [Abstract][Full Text] [Related]
17. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer.
Niloff JM; Knapp RC; Lavin PT; Malkasian GD; Berek JS; Mortel R; Whitney C; Zurawski VR; Bast RC
Am J Obstet Gynecol; 1986 Jul; 155(1):56-60. PubMed ID: 3460341
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of second-look laparotomy for ovarian cancer: second-look vs. serum CA125.
Liu L; Hong W; Hou Y; Yao Z; Wu A; Wang X
Chin Med Sci J; 1991 Jun; 6(2):96-9. PubMed ID: 1804384
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients.
Hising C; Anjegård IM; Einhorn N
Am J Clin Oncol; 1991 Apr; 14(2):111-4. PubMed ID: 2028919
[TBL] [Abstract][Full Text] [Related]
20. [Relationship between serum CA125 level and second-look findings in ovarian cancers].
Liu LY
Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):287-9. PubMed ID: 1327702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
